Singh et al., however, found a distinct hyperacetylation of PML-RARa-binding sites in high-risk APL patients compared to low-risk APL samples, both untreated and post-treatment with all-trans-retinoic acid (Singh et al., 2018). The gene discussed is PML; the disease is acute promyelocytic leukemia.